HIMS News & Events

The FDA is moving toward allowing compounding pharmacies to produce over a dozen injectable peptides that were previously banned due to safety concerns, The New York Times' Christina Jewett and Dani Blum reports. In 2023, 14 such peptides, unapproved by the FDA and marketed with unproven cosmetic, anti-aging, or disease-fighting claims, were removed from the list of compounds these pharmacies could legally produce for individualized patient use. Health Secretary Robert F. Kennedy Jr. has said in recent podcast appearances that he is pushing for the F.D.A. to reverse the prohibition on the peptides, which include some that act as growth-hormone stimulators. Shares of Hims & Hers, which sells peptide-based products, are up nearly 4% in morning trading to $19.47.

Novo Nordisk (NVO) announced a new multi-month subscription program for Wegovy that provides eligible self-pay patients who enroll in the program through select telehealth providers a lower, predictable monthly price. The program is designed to reduce cost uncertainty and help people start and stay on FDA-approved obesity treatment. This subscription program will be available beginning March 31, 2026, through Ro, WeightWatchers (WW), LifeMD (LFMD), with Hims & Hers (HIMS), Sesame, and others to follow soon. Patients can save up to $600/year on the Wegovy pill and up to $1,200/year on the Wegovy injection with a 12-month subscription, Novo Nordisk said.